PBK and non-small cell lung carcinoma: PBK/TOPK overexpression could also predict poor prognosis, including shortened overall survival and time to recurrence, because of its effect on promoting tumor metastasis in patients with stage I lung adenocarcinoma and non-small-cell lung cancers (NSCLC) [36,37,47,48].